Abstract | INTRODUCTION: METHODS: We performed a retrospective case review using the National United States Veterans Affairs Health Administration electronic medical record system. We analyzed prevalence, demographics, disease characteristics, and treatment outcomes in SPS patients who were anti-GAD65 antibody positive. RESULTS: Fifteen patients met our criteria. Point prevalence was 2.06 per million, and period prevalence was 2.71 per million. Men to women ratio was 14:1. All patients benefitted from treatment with symptomatic antispasmodic agents. Ten of 15 patients received intravenous immunoglobulin, with a majority demonstrating stable or improved modified Rankin scores. DISCUSSION: This investigation was a large North American epidemiological study of SPS with predominantly male patients. Symptomatic therapy was beneficial for most patients, with less clear sustained benefit of immunotherapy. Muscle Nerve 58:801-804, 2018.
|
Authors | Jonathan R Galli, Sharon D Austin, John E Greenlee, Stacey L Clardy |
Journal | Muscle & nerve
(Muscle Nerve)
Vol. 58
Issue 6
Pg. 801-804
(12 2018)
ISSN: 1097-4598 [Electronic] United States |
PMID | 30192027
(Publication Type: Journal Article)
|
Copyright | © 2018 Wiley Periodicals, Inc. |
Chemical References |
- Autoantibodies
- Immunoglobulins, Intravenous
- Immunologic Factors
- Glutamate Decarboxylase
- glutamate decarboxylase 2
|
Topics |
- Adult
- Autoantibodies
(blood)
- Female
- Glutamate Decarboxylase
(immunology)
- Humans
- Immunoglobulins, Intravenous
(therapeutic use)
- Immunologic Factors
(therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Severity of Illness Index
- Stiff-Person Syndrome
(blood, diagnosis, epidemiology)
- United States
(epidemiology)
- United States Department of Veterans Affairs
(statistics & numerical data)
- Veterans
(statistics & numerical data)
|